A report on the outcomes of allogeneic HCT in 143 patients with neuroblastoma reported to CIBMTR (Center for International Blood and Marrow Transplant Research) in 1990-2007. Outcomes were analyzed as a whole, and separately based on whether patients had undergone prior autologous HCT (n=97) or not (n=46). One-year and five-year overall survival were 50% and 7% for patients with prior autologous HCT and 59% and 29% for those without prior autologous HCT, respectively. The authors note that although their retrospective study could not determine why either strategy was chosen for patients, they conclude that allogeneic HCT has a better chance to cure neuroblastoma patients who have not had a prior autologous transplant.
Allogeneic HCT for Neuroblastoma
Mar 2013